Bladder Cancer, UTUC More Common in Kidney Transplant Recipients
A study found that bladder cancer and UTUC occurred in 122.22 and 113.97 per 100,000 persons per year, respectively, among kidney transplant recipients.
|The following article is part of conference coverage from the 2018 American Urological Association meeting in San Francisco. Renal and Urology News' staff will be reporting live on medical studies conducted by urologists and other specialists who are tops in their field in kidney stones, prostate cancer, kidney cancer, bladder cancer, enlarged prostate, and more. Check back for the latest news from AUA 2018.|
SAN FRANCISCO—Bladder cancer and upper tract urothelial carcinoma (UTUC) occur much more frequently among kidney transplant recipients than the general population, Jiwoong Yu, MD, and colleagues from Samsung Medical Center, Sungkyunkwan University in Seoul, South Korea reported at the American Urological Association 2018 annual meeting.
Of 2186 patients who underwent kidney transplantation at their institution during 1995 to 2016, bladder cancer and UTUC occurred in 122.22 and 113.97 per 100,000 persons per year, respectively. These rates were 25.5 and 129.5 times higher, respectively, than those in the general Korean population. A greater proportion of kidney transplant recipients, particularly female recipients, had UTUC rather than bladder cancer.
Among bladder cancer patients, kidney transplant recipients survived as well as others with their cancer. Their risk for progression, however, was significantly higher by 10 fold.
No significant differences were found in recurrence, progression, or survival among UTUC patients.
“Special attention should be paid to urothelial carcinoma in kidney transplant recipients, including urologic screening and active treatment,” Dr Yu and the team concluded.
Yu J, Hoon Lee J, Hyo Choi Y, et al. Incidence and oncological outcomes of urothelial carcinoma in kidney transplant recipients. Data presented in poster format at the American Urological Association 2018 annual meeting, San Francisco, May 18–21. Abstract MP06-19.